This is a working overview of telomerase, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-13. Anything still debated is marked as such rather than presented as settled.
The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. The chromatogram shows the main peak and any truncated or oxidised by-products, while the mass spectrum confirms the expected 390 dalton mass. Amino acid analysis can corroborate composition when a sample's origin is uncertain. Counterion content, particularly residual trifluoroacetate from purification, is frequently reported alongside purity because it shifts the net mass of the solid.
Reference material is normally supplied as a lyophilised powder in a sealed vial. Product literature typically recommends storage at minus twenty degrees Celsius or colder, protected from light and moisture. Freeze-thaw cycling is usually avoided because repeated condensation can introduce water into the vial. Working solutions are commonly prepared fresh, aliquoted, and kept cold for short periods rather than stored at ambient temperature. Labelling the date of opening helps track how long a vial has been in use.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Ala-Glu-Asp-Gly | Often abbreviated AEDG in research literature |
| Common synonyms | Epithalon, epitalon, AEDG | Spelling variants refer to the same tetrapeptide |
| Molecular formula | C14H22N4O9 | Theoretical monoisotopic mass near 390.35 Da |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Freely soluble in water | Hydrophilic peptide; dissolves in aqueous buffer |
Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.
The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.
Regulatory treatment differs by country. No formulation of epitalon holds a marketing authorisation as a medicine in the United States or the European Union, where material sold for laboratory use is handled as a research chemical and is not intended for human consumption. In Russia, several short peptide preparations from the same institute's peptide series are registered medicinal products, and epitalon appears in that national context. Elsewhere it is frequently offered as a cosmetic ingredient, a category with lighter requirements. Advertising claims about longevity or disease prevention are restricted in most jurisdictions, which limits how sellers describe the compound.
Freeze-dried epitalon is normally kept at minus twenty degrees Celsius in a sealed, desiccated container, protected from light. Short excursions at ambient temperature during shipping are generally tolerated, but repeated warming and cooling cycles encourage moisture uptake, which shortens shelf life. Once dissolved, the peptide is far less stable than the solid: aqueous solutions are subject to hydrolysis and to deamidation at the aspartate and glutamate residues. Working solutions are therefore held refrigerated and used within days, and repeated freezing and thawing of the same vial is best avoided.
Chemically, the molecule consists of four amino acid residues joined by three peptide bonds, with a free N-terminal amino group and a free C-terminal carboxyl group. Its molecular formula is C14H22N4O9, and its monoisotopic mass is approximately 390 daltons. The acidic glutamate and aspartate side chains give the peptide a net negative charge near neutral pH, a property that shapes its chromatographic behaviour and solubility profile. No disulfide bridges or other post-translational modifications are present, so the primary sequence alone defines the structure.
Most experimental work has been carried out in cell culture and animal models. Several reports describe changes in telomerase activity and proliferation in cultured cells, while rodent studies have examined lifespan, melatonin rhythm and reproductive endpoints. Human data remain limited, and much of the published clinical material consists of small trials with incomplete reporting of methods and controls. Whether the cell and animal findings translate into measurable effects in people is an open question, and the mechanistic basis of the reported telomerase changes is not fully established.
Compounds containing one or more elements which can exist in a variety of charge/oxidation states will have a stoichiometry that depends on which oxidation states are present, to ensure overall neutrality. This can be indicated in the name by specifying either the oxidation state of the elements present, or the charge on the ions. Because of the risk of ambiguity in allocating oxidation states, IUPAC prefers direct indication of the ionic charge numbers. These are written as an arabic integer followed by the sign (... , 2−, 1−, 1+, 2+, ...) in parentheses directly after the name of the cation (without a space separating them). For example, FeSO4 is named iron(2+) sulfate (with the 2+ charge on the Fe2+ ions balancing the 2− charge on the sulfate ion), whereas Fe2(SO4)3 is named iron(3+) sulfate (because the two iron ions in each formula unit each have a charge of 3+, to balance the 2− on each of the three sulfate ions). Stock nomenclature, still in common use, writes the oxidation number in Roman numerals (... , −II, −I, 0, I, II, ...). So the examples given above would be named iron(II) sulfate and iron(III) sulfate respectively. For simple ions the ionic charge and the oxidation number are identical, but for polyatomic ions they often differ. For example, the uranyl(2+) ion, UO2+2, has uranium in an oxidation state of +6, so would be called a dioxouranium(VI) ion in Stock nomenclature.
Developments in Britain helped to alienate the white Rhodesian population from the former mother country, namely Queen Elizabeth II's 1966 speech to the Parliament of Jamaica where she endorsed majority rule and her attempt in 1968 to block the hanging of what Rhodesians perceived as Zimbabwean nationalist terrorists. Until late 1969, Rhodesia still recognised Queen Elizabeth II as head of state, even though it opposed the British government itself for hindering its goals of independence. However she refused to accept the title Queen of Rhodesia and eventually the Smith government abandoned their attempts to remain loyal to the British Crown. In a 1969 referendum, a majority of the electorate voted to declare Rhodesia an independent republic. The hope being that this move would facilitate recognition as an independent state by the international community, but the issue of white minority rule remained and continued to hinder this effort, and like the UDI before it, the proclamation of a republic lacked international recognition. The British public overall viewed the issue of Rhodesia and UDI as a distant and anachronistic one that they cared relatively little about and saw any expedient response to it by their government as satisfactory. Most Britons saw the end of Rhodesia's white supremacist timocracy as inevitable and justified. Although the majority Britons opposed military intervention against the renegade Rhodesian state, this opinion was not uniformly held.
=== Immunophenotypic studies === Immunohistochemistry (IHC) is best performed on frozen sections of tumor (not formalin fixed material!). Histiocytoma is readily distinguished from other histiocytic disorders and cutaneous lymphoma with the aid of IHC. Our work has clearly shown that histiocytomas have the phenotype of epidermal Langerhans cells. They express CD1a, CD1b, CD1c, MHC class II, CD11c, and E-cadherin. Amongst leukocytes, E-cadherin expression is unique to Langerhans cells. Langerhans cells utilize E-cadherin to localize in the epidermis via homotypic interaction with E-cadherin expressed by keratinocytes. Histiocytomas lack expression of CD4 and Thy-1, which are consistently expressed by histiocytes in cutaneous and systemic histiocytosis. Hence cutaneous histiocytoma is a localized epidermal Langerhans cell tumor, and the rare examples of systemic spread of histiocytoma are best characterized as Langerhans cell histiocytosis (LCH) similar to that observed in humans.
A single dose of LSD (Definium Therapeutics's DT120 candidate) markedly reduced major depressive disorder symptoms versus placebo in a Phase 3 trial, with benefits lasting at least 12 weeks and no major safety concerns. LSD is a psychoplastogen, a compound capable of promoting rapid and sustained neural plasticity, an action that hypothetically might be involved in its therapeutic benefits. Preliminary evidence in humans suggests that a single dose of LSD may also temporarily benefit learning and memory. More research is needed to substantiate such notions. The British critical psychiatrist Joanna Moncrieff has critiqued the use and study of psychedelics like LSD for treatment of psychiatric disorders, highlighting concerns including excessive hype around these drugs, questionable biologically-based theories of benefit, blurred lines between medical and recreational use, flawed clinical trial findings, financial conflicts of interest, strong expectancy effects and large placebo responses, small and short-term benefits over placebo, and their potential for difficult experiences and adverse effects, among others.
== Safety == In vivo dermal sensitization studies according to OECD 429 confirmed CMDT is a strong skin sensitizer, showing a response at 0.03 wt% in the local lymph node assay (LLNA) placing it in Globally Harmonized System of Classification and Labelling of Chemicals (GHS) Dermal Sensitization Category 1A. These studies confirm that DMTMM is a less sensitizing alternative to CDMT, as suggested by anecdotal observations in the literature.
Sources: en.wikipedia.org
=== Anxiety disorders === Pregabalin is effective for treatment of generalized anxiety disorder. It is also effective for short- and long-term treatment of social anxiety disorder and in reducing preoperational anxiety. However, there is concern regarding pregabalin's off-label use due to the lack of strong scientific evidence for its efficacy in multiple conditions and its proven side effects. The World Federation of Biological Psychiatry recommends pregabalin as one of several first line agents for the treatment of generalized anxiety disorder, but recommends other agents such as those of the selective serotonin reuptake inhibitor (SSRI) class as first-line treatment for obsessive–compulsive disorder (OCD) and post-traumatic stress disorder (PTSD). For PTSD, pregabalin as complementary treatment seems to be effective.
=== Economics === In June 2020, Gilead announced that it had set the price of remdesivir at US$390 per vial for the governments of developed countries, including the United States, and US$520 for US private health insurance companies. The expected course of treatment is six vials over five days for a total cost of US$2,340. Being a repurposed drug, the minimum production cost for remdesivir is estimated at US$0.93 per day of treatment. In July 2020, the European Union secured a €63 million (US$74 million) contract with Gilead, to make the drug available there in early August 2020. In October 2020, Gilead Sciences and the European Commission announced they had signed a joint procurement framework contract in which Gilead agreed to provide up to 500,000 remdesivir treatment courses over the next six months to 37 European countries. Among the contracting countries were all 27 EU member states plus the United Kingdom, "Albania, Bosnia & Herzegovina, Iceland, Kosovo, Montenegro, North Macedonia, Norway, and Serbia". At the time, the price per treatment course was not disclosed; Reuters reported the price was 2,070 euros, thereby implying the total value of the contract (if all 500,000 courses are ordered) is approximately €1.035 billion. Under the contract, each participating country will directly place orders with Gilead and pay Gilead directly for its own orders.
== History == The British computer scientist Alan Turing laid the theoretical groundwork for artificial intelligence. His foundational 1936 paper on the Entscheidungsproblem introduced the concept of the universal computing machine. Turing's wartime efforts at Bletchley Park involved developing the Bombe, an electromechanical device that utilized heuristic search techniques to decipher Enigma codes. In 1950, Turing published his seminal paper "Computing Machinery and Intelligence" in the journal Mind, where he proposed the "Imitation Game" (now known as the Turing Test) as a criterion for machine intelligence. This period established Britain as a global leader in early computational theory and machine intelligence. During the 1960s, the UK established AI research centers, most notably at the University of Edinburgh. In 1963, Donald Michie founded a small research group that later evolved into the Department of Machine Intelligence and Perception. Michie's team developed the Freddy robots (Freddy I and Freddy II), which were early examples of robots capable of integrating vision and manipulation to assemble objects. Researchers such as Robert Kowalski at the University of Edinburgh and later Imperial College London made significant contributions to logic programming, laying the theoretical foundations for the Prolog programming language. However, the optimism of the 1960s was curtailed by the 1973 Lighthill Report.
=== Gingivectomy by electrosurgery === Electrosurgery is defined as the intentional passage of high-frequency waveforms or currents through the tissues of the body to achieve a controllable surgical effect. It has been used in dentistry for more than 60 years. Electrosurgery may be used where a blood-free environment is required, providing that there is no bone coming into contact with the instrument and good oral hygiene is maintained. The technique is not widely used due to multiple factors including cost and lack of information available on the topic. It is essential to have the presence of a circuit in an electrosurgical unit, allowing current to flow. By changing the mode of activation of this current, electrosurgery may be used for the cutting or coagulation of soft tissues. The basic types of electrosurgical techniques are coagulation, desiccation, fulguration and electrosection (cutting). The majority of clinical operations are done by electrosection. There are two main types of electrosurgical units, monopolar and bipolar. In monopolar units a separate electrode is needed, usually in the form of an indifferent plate behind the patient's back. The current begins in the electrosurgical unit and flows to the oral site through a wire and then to the secondary electrode. Heat is produced on contact with the oral tissues and cutting results. Bipolar devices have two electrodes on their cutting tip and the current travels from one to the other, which removes the need for an indifferent plate. Bipolar devices make a wider cut.
Sources: en.wikipedia.org
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine–glutamate–aspartate–glycine, also written AEDG. It was developed in Russian gerontology research and is studied for proposed effects on telomerase, melatonin regulation, and neuroendocrine function. It is not an approved pharmaceutical in the United States or the European Union.
No. Epithalamin is a peptide-rich extract prepared from bovine pineal glands, while epitalon is a short synthetic peptide designed as a defined analogue of it. The synthetic version was intended to provide a reproducible molecule with some of the same proposed biological activity.
Telomere elongation and telomerase activation have been reported in cultured human somatic cells, but evidence from living human subjects is limited and has not been independently confirmed at scale. Reported findings come largely from small studies with differing designs, so the question remains open rather than settled.
Sealed lyophilised powder is normally kept at minus twenty degrees Celsius or below, away from light and moisture. Vials are allowed to reach room temperature before opening to limit condensation. Repeated warming and cooling of the same vial is discouraged.